Dr Rami Batniji discusses how Evolysse’s cold technology manufacturing process may offer clinical advantages over traditional hyaluronic acid fillers.
As a new injectable enters the U.S. aesthetics market, plastic surgeons are taking a closer look at how its formulation may differ from established options. Evolysse is a hyaluronic acid filler developed using cold technology—an approach designed to reduce BDDE content and more closely replicate natural HA chains. Early clinical data suggests potential advantages in terms of efficiency, swelling, and immune response.
To learn more about how this product may fit into treatment plans, Plastic Surgery Practice spoke with Persana’s in-network physician Rami Batniji, MD. A board-certified facial plastic surgeon practicing in Newport Beach, Calif, Batniji shares his insights on Evolysse’s clinical performance and how it compares to other HA fillers in use today.
Plastic Surgery Practice: What should plastic surgeons know about Evolysse as it enters the U.S. injectable market, and how does it compare to existing hyaluronic acid fillers?
Rami Batniji, MD: Evolysse is a first of kind injectable hyaluronic acid gel developed with cold technology. Through this unique manufacturing process, there are less amounts of BDDE (1,4 Butanedoil ether) which is of importance because there is concern that BDDE in fillers may be immuno-stimulant and result in reactions such as delayed onset nodules in certain patients. Further, cold technology allows for longer chain hyaluronic acid gel in Evolysse and its these longer chains that are more common in nature and thus behave more similar to natural hyaluronic acid.
PSP: From a clinical perspective, what stands out about Evolysse’s formulation or performance in treating moderate to severe wrinkles like nasolabial folds?
Batniji: Evolysse has very low hydrophilic characteristics meaning less swelling is caused with this hyaluronic acid gel compared to others. As such, injections should be performed to full correction and “what you see is what you get” at the completion of the procedure. It’s also very efficient; studies showed this product provided better correction with lesser amounts of product injected.
PSP: Are there particular patient demographics or aesthetic goals that make someone a strong candidate for Evolysse over other HA fillers?
Batniji: All patients who are candidates for hyaluronic acid injections would be appropriate candidates for Evolysse.
PSP: What has been your experience with patient satisfaction and longevity of results with Evolysse so far?
Batniji: According to the study performed that was integral in achieving FDA approval for Evolysse, patient satisfaction was very high and duration was comparable to other hyaluronic acid fillers currently available in the U.S. market.
PSP: How do you see Evolysse fitting into or reshaping current treatment plans, particularly in combination with other injectables or surgical procedures?
Batniji: In this current environment, less is more with hyaluronic acid fillers. Providers and patients want natural results with less product. Evolysse has been shown to be efficient, meaning that results can be achieved with less product. It has also been shown to be more natural; it consists of longer chain hyaluronic acid which is similar to what we see in nature. And it has less BDDE, which may result in less immune mediated issues as have been seen with other hyaluronic acid fillers. The cold technology manufacturing process allows for these unique characteristics of Evolysse. PSP
Lead photo: Evolysee
